Alkermes
852 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 781-609-6000
Website: http://www.alkermes.com/
Email: mediainfo@alkermes.com
About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com .
Key Executives:
Richard F. Pops- Chairman and Chief Executive Officer
Shane Cooke- President
Kathryn L. Biberstein- Executive Vice President, Chief Compliance Officer and Chief Administrative Officer, and Secretary Alkermes plc
Iain Brown- Senior Vice President, Finance and Chief Accounting Officer
Madeline D. Coffin- Senior Vice President, Human Resources
Elliot W. Ehrich, M.D.- Executive Vice President, Research and Development
James M. Frates- Senior Vice President, Chief Financial Officer
David J Gaffin- Senior Vice President, Chief Legal Officer
Georgianna Harris, Ph.D.- Senior Vice President, Regulatory Affairs
Craig Hopkinson, M.D.- Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs
Blair C. Jackson- Senior Vice President, Business Development
Michael J. Landine- Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.- Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman- Vice President, Government Affairs and Policy
Declan O’Connor- Senior Vice President, Operations
Phil Shanahan, Ph.D.- Vice President, Quality Operations
Mark P. Stejbach- Senior Vice President, Chief Commercial Officer
Locations
Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000
Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100
Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
676 articles about Alkermes
-
Alkermes to Participate in the Goldman Sachs Healthcare Conference
6/8/2022
Alkermes plc announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 2:40 p.m. PT.
-
Well-known for its neurological drug development programs, Alkermes has firmly planted its flag as an oncology company at ASCO. Alkermes Head of Oncology Jessicca Rege spoke with BioSpace.
-
Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
6/2/2022
Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants ® program beginning on June 15, 2022.
-
Alkermes to Participate in the Jefferies Healthcare Conference
6/1/2022
Alkermes plc announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET.
-
Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
6/1/2022
ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types.
-
Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors
5/26/2022
Alkermes plc announced a series of actions as part of its ongoing commitment to strong corporate governance and regular board refreshment.
-
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
5/9/2022
Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin) at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually.
-
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
5/2/2022
Alkermes plc (Nasdaq: ALKS) today announced plans to present research related to its psychiatry portfolio at four scientific conferences during Mental Health Awareness Month in May.
-
Alkermes plc Reports First Quarter 2022 Financial Results
4/27/2022
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2022.
-
Alkermes to Report First Quarter Financial Results on April 27, 2022
4/20/2022
Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Wednesday, April 27, 2022 to discuss the company's first quarter financial results.
-
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
4/19/2022
Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
-
Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society
4/7/2022
Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International Research Society (SIRS), taking place April 6-10, 2022 in Florence, Italy.
-
Alkermes to Participate in the Stifel 2022 CNS Days
3/22/2022
Alkermes plc announced that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Stifel 2022 CNS Days on Tuesday, March 29, 2022 at 8:30 a.m. ET.
-
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
3/1/2022
Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022.
-
Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium
2/17/2022
Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy.
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022
2/16/2022
Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations for 2022.
-
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness
2/8/2022
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of LYBALVI ®.
-
Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022
2/2/2022
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Wednesday, Feb. 16, 2022 to discuss the company's fourth quarter and year-end 2021 financial results.
-
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
-
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
1/18/2022
Alkermes plc announced plans to present a poster related to nemvaleukin alfa, the company's novel, investigational, engineered interleukin-2 variant immunotherapy, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place Jan. 20-22, 2022.